Not Yet RecruitingPhase 3

A Study of Lebrikizumab in Adults With Nummular Eczema

270 participantsStarted 2026-04

Plain-language summary

The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Serious (requiring hospitalisation and/or intravenous or equivalent oral antibiotic treatment, per the Investigator's opinion)
✕. Opportunistic (as defined by Winthrop 2015) Note: herpes zoster is considered active and ongoing until all vesicles are dry and crusted over
✕. Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer), including hepatitis B virus and hepatitis C virus infections
✕. Recurring (including but not limited to herpes zoster, recurring cellulitis, and chronic osteomyelitis) with the exception of uncomplicated herpes simplex infection, which is not considered exclusionary

What they're measuring

Percentage of Participants Achieving Investigator Global Assessment (IGA) Score of 0 or 1 and a >=2-point Reduction from Baseline at Week 24

Timeframe: Baseline, Week 24

Trial details

NCT IDNCT07542483

SponsorAlmirall, S.A.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-08

Contact for this trial

Estrella Garcia

gco@almirall.com

View on ClinicalTrials.gov More Nummular Eczema trials